Andrew Dublin, MD
Interventional Cardiology · Walnut Creek, CANPI 1215085246
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,160 of the $59,242 with a category attached, or 67.8%. 50 manufacturers reported payments, led by Johnson & Johnson at 31.4% of the total. Reporting peaked in 2021 at $20,726 and has fallen 89.1% since, to $2,255 in 2025.
Across 690 payments — averaging $85.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$19K
- AstraZeneca$17K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
- Cathworks, Inc.$3K
- Boston Scientific$1K
- Abbott$1K
- plus $10K from 44 others
Across 69 payments — averaging $5572.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$263K
- Procyrion, Inc.$64K
- CSL Behring$58K
What the payments were for
- Consulting fees$2,8005%
- Speaking & faculty fees$40,16068%
- Travel & lodging$2690%
- Food & beverage$15,82527%
- Education$1880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$17,137
- FARXIGA$16,549
- LifeVest$7,734
- FFRangio$2,500
- Rapiblyk$1,624
- Impella$241
- TRICLIP$186
- WATCHMAN Access System$151
- WATCHMAN FLX$150
- LATITUDE$146
- ATRICLIP LAA EXCLUSION SYSTEM$145
- LINQ II$120
How this compares
$59,242 in reported general payments places this provider in the 85th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 391 | $524,035 |
| XareltoRivaroxaban | 159 | $230,688 |
| Repatha SureclickEvolocumab | 164 | $213,737 |
| MultaqDronedarone Hcl | 88 | $166,428 |
| FarxigaDapagliflozin Propanediol | 139 | $149,977 |
| EntrestoSacubitril/Valsartan | 98 | $131,048 |
| JardianceEmpagliflozin | 78 | $98,343 |
| Praluent PenAlirocumab | 46 | $55,338 |
| OzempicSemaglutide | 34 | $40,619 |
| BrilintaTicagrelor | 17 | $18,376 |
| Droxidopa | 11 | $17,427 |
| Repatha SyringeEvolocumab | 11 | $15,683 |
| Atorvastatin Calcium | 852 | $9,267 |
| Metoprolol Succinate | 471 | $8,819 |
| Ezetimibe | 237 | $8,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $494 | $524,035391 claims |
| Johnson & JohnsonXarelto | $18,581 | $230,688159 claims |
| AstraZenecaFarxiga, Brilinta | $17,119 | $168,354156 claims |
| Sanofi-aventis U.S. LLCMultaq | $250 | $166,42888 claims |
| NovartisEntresto | $594 | $131,04898 claims |
| Boehringer IngelheimJardiance | $646 | $98,34378 claims |
| Novo NordiskOzempic | $151 | $40,61934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Walnut Creek
- Mark NathanWalnut Creek$158K
- Richard ChangWalnut Creek$132K
- Andrew BennWalnut Creek$122K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.